- RecruitingPHASE1, PHASE2
A Study of BGB-11417 in Participants With Myeloid Malignancies
This study is looking at a new drug, BGB-11417, for certain blood cancers like acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Researchers want to see if it's safe, what dose works best, and if it helps people, either alone or with another treatment called azacitidine.
For: Acute Myeloid Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative NeoplasmUnited States · Australia · China - Active not recruitingPHASE1, PHASE2
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
This study is testing a new drug, BGB-11417, for people with mantle cell lymphoma that has come back or not responded to previous treatments. It aims to find the safest dose and see how well it works.
For: Mantle Cell Lymphoma · Refractory Mantle Cell Lymphoma (MCL) · Relapsed Mantle Cell LymphomaUnited States · Argentina · Belgium